Stuttgart
31.08.26 | 08:20
1,400 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07:06 | Advicenne decides to withdraw its ADV7103 New Drug Application in the USA | 230 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 20.07. | Advicenne Announces the Reimbursement of Sibnayal for the Treatment of dRTA in Spain | 349 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 16.07. | Advicenne: Net Revenue for the First Half of 2026 Driven by Reimbursement of Sibnayal and Likozam in France | 593 | Business Wire | The first half 2026 reported revenue is the first without the negative impact of early access rebates Reported revenue does not include royalties to be received from commercial partners... ► Artikel lesen | |
| 01.07. | Advicenne Announces the Unlimited Renewal of the Marketing Authorization for Sibnayal in the United Kingdom | 492 | Business Wire | Regulatory News:
Advicenne S.A. (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering... ► Artikel lesen | |
| 22.06. | Advicenne Secures Its Cash Runway to Q2 2027 through a Bond Financing of a Nominal Amount of up to €3.8 Million | 648 | Business Wire | The transaction reflects the commitment of key shareholders, such as Cemag Invest and Didier Laurens, Chairman and CEO, joined by Europe Offering and L1 Capital. Immediate funding of €1.4... ► Artikel lesen | |
| 01.06. | Advicenne Granted Reimbursement for Likozam in France and Sees Thereby Its Debt Reduced by Nearly €6 Million | 328 | Business Wire | Likozam will be reimbursed to patients starting June 12, 2026 Official reimbursement ends the "Early Access" clawback The price obtained offsets the discounts owed under the early... ► Artikel lesen | |
| 21.05. | Advicenne Announces Changes to Its Governance Following Its Annual General Meeting on May 21, 2026 | 478 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 -ALDVI), a pharmaceutical company specializing in the development and marketing of innovativetreatments for people suffering from... ► Artikel lesen | |
| ADVICENNE Aktie jetzt für 0€ handeln | |||||
| 05.05. | Advicenne Announces the Opening of a Safeguard Proceedings to Restructure Its Financial Liabilities and Finalize the Extension of Its Cash Runway | 667 | Business Wire | A proactive initiative to restructure the Company's debt A protective framework that allows for the continuation of commercial, clinical, and regulatory activities, as well as discussions... ► Artikel lesen | |
| 24.04. | Advicenne 2025 Universal Registration Document Made Available | 443 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 26.03. | Advicenne Reports Its 2025 Annual Financial Results | 934 | Business Wire | Product sales up 18.7% to €5.8 million
European end-market sales of Sibnayal rose by more than 71% to nearly €11 million
Royalties doubled to over €1.1 million
Cash position... ► Artikel lesen | |
| 02.02. | Advicenne: Official Reimbursement of Sibnayal for the Treatment of dRTA in France | 879 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 27.01. | Advicenne Receives Marketing Authorization and Reimbursement for Sibnayal in UAE | 509 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 22.01. | Advicenne: 2025 Full Year Sales | 605 | Business Wire | 2025 sales totaled €5.73m, up 18.4%
Sibnayal sales rose 36.6% to €3.01m
2025 Royalties are estimated at €1m, double the amount for 2024
End-markets estimated sales of Sibnayal... ► Artikel lesen | |
| 20.01. | Advicenne: 2026 Financial Calendar | 527 | Business Wire | Regulatory News:
Advicenne(Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 19.01. | Advicenne: FDA Has Accepted for Review the Marketing Authorization Application for Sibnayal in the United States for the Treatment of dRTA | 507 | Business Wire | The US regulatory agency has set the target date for the final approval decision, known as the PDUFA date, as of September 3rd, 2026.
Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746... ► Artikel lesen | |
| 12.01. | Advicenne Has Successfully Renewed the Marketing Authorization of Sibnayal in European Union | 418 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 04.11.25 | Advicenne Has Submitted to US FDA the Registration Application for Sibnayal in dRTA Treatment | 606 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 19.09.25 | Advicenne Reports First Half Financial Results as of June 30, 2025, and Updates on Its Activities | 660 | Business Wire | Sibnayal® end-market sales (Europe and Middle East) up 103% to €5.5 million
H1 products sales and royalties totaled €3.1 million, up 20%
Financial visibility extended to the fourth... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 48,730 | +0,39 % | Bayer-Aktie: Score 1 - Warum das Rekordurteil nichts ändert - Warren Wise Podcast | Ein Risiko weniger ist noch keine Rendite: Der Oberste US-Gerichtshof hat im langen Glyphosat-Streit zugunsten von Bayer entschieden. Die Aktie sprang daraufhin deutlich nach oben. Trotzdem steht Bayer... ► Artikel lesen | |
| PFIZER | 24,045 | -0,35 % | Money, Money, Money: Bei RE Royalties, Aumann und Pfizer kommen Dividendenliebhaber auf ihre Kosten | Dividenden sind weit mehr als ein Trostpflaster für schwächere Börsenphasen. Gewinnausschüttungen steuern in der Regel einen großen Teil der Gesamtrendite von Aktien bei. Zudem schwanken Dividenden... ► Artikel lesen | |
| ABBVIE | 220,60 | 0,00 % | Compass Pathways und Definium nähern sich dem Markt: Warum der nächste Engpass bei Psychedelika Emyria in den Fokus rückt | ||
| ELI LILLY | 1.010,00 | -0,30 % | Aktie rutscht ab: Novo Nordisk wird auf Sell abgestuft - und die Zweifel reichen bis 2027 | © Foto: Steffen Trumpf - dpaDas neue Kursziel der Deutschen Bank liegt klar unter dem aktuellen Börsenkurs. Gleichzeitig rückt die Wegovy-Pille in China einen Schritt näher an den Markt Enthaltene Werte:... ► Artikel lesen | |
| MERCK & CO | 127,70 | -0,20 % | Merck, Vidac Pharma, Moderna - Neue Krebswaffen elektrisieren die Börse | Ein Durchbruch in der Krebsforschung versetzte die Börse in der vergangenen Woche in Euphorie. Eine personalisierte mRNA-Therapie hat erstmals in einer großen Phase-3-Studie entscheidende Ziele erreicht... ► Artikel lesen | |
| BRISTOL-MYERS SQUIBB | 57,35 | -0,17 % | Bristol Myers stößt bei seiner Milliarden-Zelltherapie an Grenzen - warum Skalierung jetzt zum entscheidenden Wettbewerbsvorteil wird | ||
| INNOCAN PHARMA | 1,430 | -2,39 % | KURSEXPLOSION bei InnoCan Pharma: 3,02% Plus - Aktie sorgt für Aufsehen | ||
| DOCMORRIS | 11,470 | -2,05 % | DEUTSCHE BANK RESEARCH stuft DocMorris auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für DocMorris von 11,5 auf 12,5 Franken angehoben und die Einstufung auf "Buy" belassen. Die Turnaround-Story gewinne an Glaubwürdigkeit... ► Artikel lesen | |
| INCYTE | 106,25 | -1,02 % | H.C. Wainwright bestätigt Kursziel für Incyte Aktie bei 150 US-Dollar | ||
| SINOPHARM | 1,725 | -1,26 % | SINOPHARM (01099): ANNOUNCEMENT PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD FOR THE SIX MONTHS ENDED 30 JUNE 2026 | ||
| HALEON | 4,329 | +0,02 % | Jefferies zu Haleon: Starke Margen, aber Zweifel am Wachstumskurs | ||
| HAPPY BELLY FOOD GROUP | 1,000 | 0,00 % | Happy Belly Food Group Inc.: Happy Belly Food Group Reports Record Results of $28.4M in Q2 System Wide QSR Sales with Year Over Year Growth of 75% | Toronto, Ontario--(Newsfile Corp. - August 26, 2026) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 59,78 | 0,00 % | Biotech Stocks At 52-Week Highs - Eton Pharmaceuticals +44%, DexCom, Oruka Therapeutics, Concentra Group Holdings Parent, AtaiBeckley | INDIANAPOLIS (dpa-AFX) - The following biotech stocks reached 52-week highs on August 14, 2026, following positive quarterly reports or an announced upcoming acquisition. Eton Pharmaceuticals... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 15,310 | -0,13 % | Generate Biomedicines stock price target raised to $30 by H.C. Wainwright on asthma data | ||
| KAZIA THERAPEUTICS | 13,590 | +0,07 % | Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering | SYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing... ► Artikel lesen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADVICENNE finden Sie auf Wallstreet Online.